news.cision.com

MilDef Group AB's Nomination Committee consists of the following members:· Johan Ståhl, appointed by Svolder AB (publ), Chair of the Nomination Committee · Peter Lundkvist, appointed by Tredje AP-fonden · Marianne Trolle, representing her own ownership in MilDef · Björn Karlsson, Chair of the Board in MilDef Information about the Nomination Committee's work is available on MilDef's website Nomination Committee – MilDef Investors . Shareholders who wish to submit proposals to the Nomination

Kieran Long appointed new Museum Director of Amos Rex

Kieran Long has been appointed Museum Director of Amos Rex. He is relocating from Stockholm, where he has served as the director at ArkDes, the Swedish Centre for Architecture and Design. Long will assume his new role in early February 2024. Kai Kartio, who has successfully guided Amos Rex from concept to its fifth year, will continue to contribute to Amos Rex in a Senior Advisor capacity. [A person wearing glasses and a suit Description automatically generated] Kieran Long on the domes of Amos Rex. Photo: Cata Portin Amos Rex, which burst onto the scene with a bang in 2018,

Voi supports Road Safety Week to encourage safe winter riding

Above: Road Safety Week graphic Credit: Brake Friday 17 November 2023, UK: Voi, the UK’s leading micromobility operator, is supporting Road Safety Week 2023 by encouraging its riders to stay safe this winter.From 19-25 November, road safety charity Brake holds its annual week of road safety awareness-raising. Voi will be reminding riders to ride safely by sharing advice from Brake as well as its own top tips for safe and considerate e-scooter riding across its channels. Voi’s top tips for riding safely and sustainably this winter include: 1. Turn on the ‘Beginner’

Careium ranked as number one on substantial UK framework

Fri, Nov 17, 2023 08:43 CET

Careium has been awarded a significant contract for the supply of telecare equipment as part of a re-tendered framework agreement. It covers the requirements of Leeds City Council and Kirklees Council, Wakefield Metropolitan District Council, East Riding of Yorkshire Council, City of Bradford Metropolitan District Council, Calderdale Metropolitan Borough Council and Middlesborough Council. The framework will provide telecare equipment that will promote and maintain the independence and well-being of residents who require such support. The tender included a rigorous assessment of products,

MyFirstApp Sweden AB (publ) Interim Report 3 - 2023

Financial overview +-----------------------------+-------+-------+----------+----------+----------+|Consolidated income statement|Q3 2023|Q3 2022|Q1-Q3 2023|Q1-Q3 2022|Helår 2022|+-----------------------------+-------+-------+----------+----------+----------+|Net revenue (msek) |0,6 |0 |1,5 |0 |0,4 |+-----------------------------+-------+-------+----------+----------+----------+|EBITDA (msek) |−0,2 |0 |−1,8 |0 |0 |+-----------------------------+-------+-------+----------+----------+----------+

Transcom partners with Netomi to set a new standard in customer experience

Fri, Nov 17, 2023 08:35 CET

Transcom, a global leader in digital Customer Experience (CX) is proud to announce a strategic partnership with Netomi, a pioneering leader in Artificial Intelligence (AI) for CX, to unleash the power of GenAI at scale in the customer experience industry. At the center of this partnership are Transcom’s global customers that include a combination of innovative scale-ups and globally recognized enterprise brands, who collectively have over 300,000 customer support agents. This dynamic partnership sets a new standard in customer experience excellence by empowering agents with field-proven AI

BoMill Q3 Report July – September 2023

BoMill AB (”BoMill” or the “Company”) hereby publishes the Interim Report for the period July 1 – September 30, 2023. The Interim Report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.Focus on commercial development – new orders and strategic partnerships CEO Andreas Jeppsson comments: “A new order on BoMill InSight™ and new partnerships with leading companies expanding our distribution network in strategic markets, is the result of our intense commercial activities and the success of our first BoMill InSight™ installations.”

Aker Solutions ASA: Key information relating to full redemption of bond loan

November 17, 2023 — This information is published in accordance with the requirements of the Continuing Obligations.Issuer: Aker Solutions ASAISIN for bond loan: NO0010853286Original maturity date: June 3, 2024New maturity date: December 4, 2023Redemption price: 100.50%Other information: N/A This information is published in accordance with the requirements of the Continuing Obligations.

Pharmacolog publishes interim report January - September 2023

Pharmacolog i Uppsala AB (publ) announces today that the interim report for the period January – September 2023 has been published.The annual report is attached as a PDF and is available on the company’s website:https://pharmacolog.com/investor-relations-2/financial-reports/ (Swedish only). Third quarter July 1 - September 30, 2023Consolidated net sales for the third quarter amounted to KSEK 1 361 (3 087).The operating result for the quarter amounted to KSEK -4,418 (-3,246).Net earnings per share for the quarter were SEK -0.07 (-0.20) before dilution and SEK -0.04 (-0.19) after

LEAX Interim Financial Report Q3 2023

Quarterly results lower but strategic momentum continuesThe third quarter in summary • Net Sales increased to SEK 457.9 million (445.9) • Operating profit decreased to SEK -12.6 million (-5.7) • Earnings before tax (EBT) decreased to SEK -30.3 million (-12.5) • Net income for the period decreased to SEK -33.1 million (-16.4) • Cash flow from operating activities amounted to SEK 20.1 million (17.2) The first nine months in summary •

Interim report January–September 2023

Profits exceed expectations despite uncertain timesTHIRD QUARTER 2023 2023 2022 2023 2022 2022SEK million Jul–Sep Jul–Sep Jan–Sep Jan–Sep Jan–DecNet sales 200 163 648 455 848Pro rata sales* 196 162 612 433 773Other operating income 2 -1 3 33 35EBITDA 8 -2 37 28 123EBIT -8 -17 -

CLS publishes interim report January – September 2023

Summary of the interim report (relates to the Group) First nine months (01/01/2023–09/30/2023) · Net sales totaled SEK 3,817,000 (SEK 1,973,000). · Profit/loss after financial items totaled SEK –55,227,000 (SEK -62,192,000). · Basic and diluted earnings per share totaled SEK -0.12 (SEK -0.9). · The equity ratio at September 30, 2023, was 86% (34%). The third quarter (07/01/2023 – 09/30/2023) · Net sales totaled SEK 1,978,000 (SEK 884,000). · Profit/loss after financial items totaled SEK –17,247,000 (SEK -30,374,000). · Basic and diluted earnings per

Cereno Scientific publishes the interim report for Q3 2023 (July 1 – September 30)

The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2023 (July 1 – September 30).Summary of the interim report for Q3 2023 (July 1 – September 30) Cereno Scientific Group · Result after financial items was SEK -11,076,974 (-7,248,364) · Earnings per share was SEK -0.05 (-0.06) before dilution and SEK -0.05 (-0.04) after dilution · The equity/assets ratio was 95.4% (93.2%) · Cash and bank balance was SEK 68,455,542 SEK (36,569,272) Parent company · Result after financial items was SEK -11,076,973 (-7,215,192) ·

Interim Report January - September 2023

Fri, Nov 17, 2023 08:15 CET

The quarter in brief Jul 1st – Sep 30th Jan 1st – Sep 30th 20232023 · Net sales amounted to EUR 11 333 · Net sales amounted thousandto EUR 3 749 thousand (EUR 18 693 thousand in same period last(EUR 5 794 thousand in year)Q3 last year) · EBITDA of EUR 1 158 thousand (EUR 389 · EBITDA of EUR 564 thousand) and EBITDA margin of 10.2%thousand (EUR 24 (2.1%)thousand) and EBITDA · EBIT of EUR 1 050 thousand (75) andmargin of 15% (0.4%) EBIT margin of 9.3% (0.4%) · EBIT

BioStock: Respiratorius’ CEO: “Strong belief but patience regarding agreement”

Lund-based Respiratorius continues talks to reach an agreement regarding the drug candidate VAL001. The discussions are now focused on already established contacts, the company states in its newly released Q3 report. When BioStock contacted CEO Johan Drott to get his view of the past quarter, he was hopeful of reaching an agreement.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/respiratorius-ceo-strong-belief-but-patience-regarding-agreement/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Nordea cancels repurchased shares

Fri, Nov 17, 2023 08:15 CET

Nordea Bank AbpStock exchange release – Total number of voting rights and capital17 November 2023 at 9.15 EET Nordea has today cancelled 13,500,394 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,535,389,326. The total number of votes attached to the shares is 3,535,389,326. The cancellation of the shares was registered with the Finnish Trade Register on 17 November 2023. The company holds 588,029

Assemblin wins a multi-technical installation assignment in a new R&D facility in Lund

Assemblin has been contracted by Skanska to design and install electrical, heating, water, cooling and gas technology in a new R&D facility in Lund (the Höjdpunkten 5 property). The value of the installation assignment is estimated at SEK 85 million.On behalf of property company Vectura, Skanska is to build a new facility of approximately 24,000 m[2] with offices, a laboratory and a test environment. Groundwork has begun and the buildings are scheduled for completion late 2025. Skanska has contracted Assemblin to assume responsibility for the electrical and heating & sanitation

Fortum and Studsvik partner to explore possibilities for new nuclear in Sweden

FORTUM CORPORATION PRESS RELEASE 17.11.2023 Fortum and the Swedish nuclear technology company Studsvik have signed a Memorandum of Understanding (MoU) to explore conditions for new nuclear in Sweden. The collaboration is part of Fortum’s ongoing feasibility study to explore business opportunities in new nuclear both in Finland and Sweden. The agreement supports Fortum’s strategic priorities to deliver reliable and clean energy and to drive decarbonisation in industries by providing clean energy and CO2-free solutions to its customers. “A lot of new electricity generation will be

Implantica presents the third quarter 2023 on November 22 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the third quarter 2023 at 15:00 CET on November 22. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.The presentation will be in English via an audiocast with teleconference: If you wish to participate via webcast, please use the following link: · https://ir.financialhearings.com/implantica-q3-2023 If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the

Truqap approved in US for HR+ breast cancer

17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN) Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in the biomarker-altered population AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of

NCC builds new treatment plant in Österåker, Sweden